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S U M M A R Y
Objective: There have been no long-term studies on trends in antibiotic resistance (ABR) on a national
scale in India. Using a private laboratory network, the ABR patterns of organisms most commonly
associated with bacteremia, obtained from patients across India between 2008 and 2014, were
examined.
Methods: A retrospective study of patient blood cultures collected over a 7-year period (January 1, 2008–
December 31, 2014) was conducted. Data on the microorganism(s) identiﬁed and their antimicrobial
susceptibility were obtained from SRL Diagnostics (Mumbai, India).
Results: Of 135 268 blood cultures, 18 695 (14%) had at least one identiﬁed pathogen. In addition to
continual high rates of methicillin-resistant Staphylococcus aureus (MRSA; approximately 44.2%), high
resistance to nalidixic acid among Salmonella Typhi (98%) was observed, and carbapenem resistance
increased in both Escherichia coli (7.8% to 11.5%; p = 0.332) and Klebsiella pneumoniae (41.5% to 56.6%;
p < 0.001). Carbapenem resistance was also stable and high for both Acinetobacter species
(approximately 69.6%) and Pseudomonas aeruginosa (approximately 49%). Resistance was also detected
to colistin in the Gram-negatives and to vancomycin and linezolid in S. aureus.
Conclusion: Increasing resistance to antibiotics of last-resort, particularly among Gram-negatives,
suggests an urgent need for new antibiotics and improved antimicrobial stewardship programs in India.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Antibiotic resistance (ABR) is a major public health problem
worldwide and is associated with adverse health and economic
consequences.1 In India, a combination of mostly single-center
studies and a few multicenter laboratory-based studies have
shown a high prevalence of antibiotic resistance among common§ Preliminary results of this study were presented at the International Conference
on Prevention & Infection Control (ICPIC), Geneva, Switzerland, June 16–19, 2015.
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(http://creativecommons.org/licenses/by/4.0/).bacterial pathogens recovered from community- and hospital-
acquired infections.2–7 However, there have been no long-term
studies on trends in ABR on a national scale in India.
Antimicrobial resistance surveillance on a national scale is
critical because it provides information on the extent of
established resistance rates, as well as emerging patterns of
resistance. Understanding how resistance is changing is important
for (1) establishing prescribing guidelines, (2) determining
investment in new therapies, and (3) improving the targeting of
campaigns to reduce antimicrobial resistance. It also provides a
baseline for future analysis and comparison with other countries.
Rising rates of ABR in India are a signiﬁcant concern because of
the high burden of bacterial diseases8 and the poor health systemociety for Infectious Diseases. This is an open access article under the CC BY license
Figure 1. Geographic locations of the 696 collection centers with positive blood
cultures.
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vaccination coverage and other public health measures. In this
study, data from a large private laboratory network were used to
examine the resistance patterns of the organisms most commonly
associated with bacteremia in patients across India for the period
January 2008 to December 2014.
2. Methods
This was a retrospective study of patient blood cultures
collected over a 7-year period (2008–2014). Data on the
microorganisms identiﬁed and their antimicrobial susceptibility
were obtained from the SRL Limited laboratory network (Mumbai,
India). The network includes 5700 collection centers spread across
26 of 29 states and two of seven Union Territories (UT). A collection
center is a ﬁeld site from where samples are collected based on
physician orders. The collection centers include private hospitals
(tertiary care, secondary care), diagnostic laboratories, and home
collection agencies. Culture specimens collected are transported to
the nearest of four reference laboratories located in four regions of
the country (Figure 1) for isolation, organism identiﬁcation, and
antimicrobial susceptibility testing. The BACTEC 9050 (Becton
Dickinson Microbiology Systems, Sparks, MD, USA) automated
system was used to process blood cultures at all four reference
laboratories.
Data were retrieved electronically from the actual patient
reports. The following information was obtained: (1) ﬁnal blood
culture result (positive growth or no growth); (2) organism
identiﬁed if the culture was positive; (3) interpreted susceptibility
results for tested antimicrobials (susceptible, intermediate resis-
tance, or resistant); (4) patient identiﬁer and demographic
information (age, sex); (5) collection center information (name
and geographical location); and (6) date of specimen collection.
Organism identiﬁcation and antimicrobial susceptibility testing
were performed using the broth microdilution methodology
(MicroScan panels, Siemens, Sacramento, CA, USA) in all reference
laboratories. Categorical result interpretations (susceptible, inter-
mediate, and resistant) were based on up-to-date Clinical and
Laboratory Standards Institute (CLSI) criteria at the time of
testing.9 All culture-positive samples were considered without
further interpretation of the results regarding clinical relevance.
The analysis considered all blood culture tests reported
between January 1, 2008, and December 31, 2014. To avoid bias
from duplicate cultures, data were ﬁltered to retain only the ﬁrst
isolate from a patient. Identiﬁed microorganisms were stratiﬁed by
year, age (<1, 1–17, 18–49, 50–64, and 65+ years), sex, and state or
territory. Intermediate susceptible isolates were grouped with
resistant isolates, as is now standard practice in the literature.10
Antimicrobial susceptibility results for major bacterial pathogens
to clinically important antimicrobial agents were examined. The
organisms examined were coagulase-negative staphylococci
(CoNS), Salmonella Typhi and Paratyphi A, Escherichia coli,
Klebsiella pneumoniae, Acinetobacter species, Staphylococcus aureus,
Pseudomonas aeruginosa, Enterococcus faecium, and Enterococcus
faecalis. Resistance was deﬁned at the antibiotic class level using
data from at least one of the several agents within the same class.
For third-generation cephalosporins, susceptibility results were
reported for ceftriaxone, cefotaxime, or ceftazidime for
Enterobacteriaceae. For all organisms, carbapenem resistance
was deﬁned as intermediate resistance or resistance to merope-
nem or imipenem. Fluoroquinolone resistance for all organisms
was deﬁned as intermediate resistance or resistance to ciproﬂoxa-
cin or levoﬂoxacin, except for Salmonella species, where nalidixic
acid was considered. Aminoglycoside resistance for all organisms
was deﬁned as intermediate resistance or resistance to gentamicin,
tobramycin, or amikacin. As minimum inhibitory concentration(MIC) values were not available in the database, the resistance
percentages for pathogen–antibiotic combinations in the years
prior to the change in MIC breakpoints are not displayed.
2.1. Statistical analysis
Unadjusted resistance rates were calculated for each year as the
number of resistant isolates as a proportion of total isolates tested.
The Chi-square test (Cochran–Armitage) for linear trend was used
to test the signiﬁcance of annual trends. A p-value of 0.05 was
considered statistically signiﬁcant. All statistical analyses were
performed using Stata software, version 12 (StataCorp, TX, USA).
This study was approved by the Institutional Ethics Committee of
the Public Health Foundation of India.
3. Results
3.1. Number and distribution of laboratories and cultures
A total of 135 268 blood cultures from unique persons were
identiﬁed in the database for the period January 2008 to December
2014. Of these, 18 695 (14%) cultures were positive. Overall, the
data came from 1820 unique collection centers spread across
425 cities and 27 states (including two UTs). The median number of
blood cultures obtained from one collection center was 3
(interquartile range 1–99). Of the 1820 collection centers, 1409
(77.4%) contributed less than 11 blood cultures over 8 years
(Figure 2). Positive blood cultures were identiﬁed at 696 of the
centers spread across 185 cities, 25 states, and two UTs. The
geographic distribution of collection centers contributing positive
culture data is illustrated in Figure 1. Of the positive cultures, 79%
were contributed by 20 collection centers that are tertiary care
hospitals located in seven major cities (Figure 1), and 92.1% of
positive cultures were from one UT (Delhi, 27.4%) and ﬁve states:
Figure 2. Blood culture contribution, by collection center.
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West Bengal (5.5%), and Karnataka (4.3%). Overall, Delhi UT had the
highest contribution, with 34% of the total cultures and 27.4% of
the positive cultures (Table 1). Approximately 62% of the total and
positive cultures were from males and about 35% of the total
cultures and 30% of the positive cultures were from persons aged
18–49 years (Table 1). Data on the distribution of total and positive
cultures by year, age, sex, and state are given in the Supplemen-
tary Material (Tables S1 and S2, respectively).
3.2. Pathogen distribution
Of the 18 695 cultures that tested positive for at least one
pathogen, 93.6% were bacteria and 6.4% were fungi. About 87.5% of
pathogens were from one of 10 pathogen groups: CoNS (23.2%),
Salmonella species (17.6%), E. coli (12.0%), Klebsiella species (7.9%),Table 1
Distribution of total and positive blood cultures
Total blood cultures Positive cultures
(n = 135 268) (n = 18 695)
Number (%) Number (%)
Sex
Male 83 055 (61.4) 11 561 (61.9)
Female 50 904 (37.6) 6904 (36.9)
Unknown 1309 (1.0) 220 (1.2)
Age, years
<1 10 446 (7.7) 1814 (9.7)
1–17 19 595 (14.5) 2719 (14.5)
18–49 46 955 (34.7) 5601 (30.0)
50–65 28 661 (21.2) 4093 (21.9)
>65 29 246 (21.6) 4392 (23.5)
Unknown 365 (0.3) 76 (0.4)
Year
2008 5381 (4.0) 695 (3.7)
2009 8553 (6.3) 1334 (7.1)
2010 14 731 (10.9) 2062 (11.0)
2011 21 709 (16.0) 3134 (16.8)
2012 29 676 (21.9) 3943 (21.1)
2013 29 706 (22.0) 3887 (20.8)
2014 25 512 (18.9) 3640 (19.5)
State
Delhi 45 967 (34.0) 5128 (27.4)
Maharashtra 16 083 (11.9) 2061 (11.0)
Rajasthan 23 273 (17.2) 4245 (22.7)
Uttar Pradesh 24 777 (18.3) 3956 (21.2)
West Bengal 7328 (5.4) 1021 (5.5)
Karnataka 5557 (4.1) 799 (4.3)
Other 12 283 (9.1) 1485 (7.9)S. aureus (5.8%), Candida species (5.8%), Acinetobacter species
(5.6%), Pseudomonas species (4.4%), Enterococcus species (2.8%),
and Enterobacter species (2.5%). The remaining 12.5% of the
identiﬁed pathogens included a wide variety of organisms
(Supplementary Material, Table S3).
CoNS were the most common bacteria isolated in all years
except 2008 and 2011 (Table 2). Among Salmonella species, 67%
were Salmonella Typhi and 25% were Salmonella Paratyphi A. The
database showed 66 polymicrobial cultures (cultures with more
than one organism isolated). The three most common pathogens
affecting infants (<1 year) were CoNS, K. pneumoniae, and Candida
species. However, among pediatric individuals (aged 1–17 years)
and young adults (aged 18–49 years), Salmonella species were the
most common pathogens isolated. The three most common
pathogens affecting older patients (>50 years) were CoNS, E. coli,
and K. pneumoniae. More detailed information on the distribution
of bacterial pathogens by age, sex, and state is given in the
Supplementary Material(Table S4).
3.3. Antimicrobial susceptibility
With regard to Gram-negative organisms, the average nalidixic
acid resistance for all years among Salmonella Typhi was 98%
(n = 190) and among Salmonella Paratyphi A was 96% (n = 67).
Ampicillin and trimethoprim–sulfamethoxazole resistance among
Salmonella Typhi decreased over the study period, dropping from
13.1% (n = 107) to 5.3% (n = 282) (p = 0.01) and from 17.1% (n = 70)
to 4.2% (n = 96) (p < 0.001), respectively (Figure 3). Resistance to
third-generation cephalosporins among Salmonella species was
low, with 0.8% (n = 1841) of Salmonella Typhi and 1.1% (n = 657) of
Salmonella Paratyphi A being resistant for all years (Table 3).
Carbapenem resistance increased among E. coli (from 7.8%
(n = 282) in 2011 to 11.5% (n = 426) in 2014; p = 0.332) and among
K. pneumoniae (from 41.5% (n = 183) to 56.6% (n = 318); p < 0.001);
however the increase was statistically signiﬁcant only for K.
pneumoniae (Figure 4). Among Acinetobacter species and P.
aeruginosa, average carbapenem resistance was 69.6% (n = 994)
for all years and 49% (n = 344) for the years 2012–2014,
respectively, with no signiﬁcant change in the trend observed
for either organism during the study period (Figure 4). Colistin-
resistant strains of E. coli, K. pneumoniae, Acinetobacter species, and
P. aeruginosa were also detected as early as 2012, with resistance
reaching 3.2% (n = 155) and 3.1% (n = 192) for K. pneumoniae and E.
coli isolates, respectively, in 2014.
Among Gram-positive organisms, the average proportion of
methicillin resistance and linezolid resistance in CoNS for all years
was 73% (n = 2488) and 0.4% (n = 3579), respectively. Overall,
three vancomycin-resistant CoNS isolates were observed during
the study period (Table 3). Among S. aureus, the average
proportion of methicillin-resistant S. aureus (MRSA) for all years
was 44.2% (n = 608), with no signiﬁcant change during the study
period. Overall, two vancomycin-resistant S. aureus (VRSA), nine
vancomycin-intermediate S. aureus (VISA), and 17 linezolid-
resistant S. aureus (LRSA) isolates were reported during the study
period. The average proportion of vancomycin resistance in E.
faecium and E. faecalis for all years was 16.6% (n = 235) and 2.4%
(n = 169), respectively, with no signiﬁcant change during the
study period.
4. Discussion
This study examined the ABR prevalence of bloodstream
isolates obtained from patients across India. It greatly expands
on prior studies of antimicrobial resistance in India,2–7 providing
detailed long-term descriptions of the proﬁle and ABR patterns of
organisms isolated in blood cultures from various regions of India.
Table 2
Ten most common organisms among positive cultures, 2008–2014; n (%)
Organism 2008 2009 2010 2011 2012 2013 2014 Total
CoNS 117 (16.8) 313 (23.4) 609 (29.5) 660 (21.1) 1031 (26.2) 792 (20.4) 815 (22.4) 4337 (23.2)
Salmonella speciesa 149 (21.4) 261 (19.5) 396 (19.2) 730 (23.2) 587 (14.9) 634 (16.3) 524 (14.4) 3281 (17.6)
Escherichia coli 66 (9.5) 166 (12.4) 202 (9.8) 312 (10.0) 501 (12.7) 495 (12.7) 496 (13.6) 2238 (12.0)
Klebsiella species 50 (7.2) 78 (5.9) 134 (6.5) 210 (6.7) 289 (7.3) 321 (8.3) 399 (11.0) 1481 (7.9)
Staphylococcus aureus 65 (9.4) 76 (5.7) 91 (4.4) 176 (5.6) 231 (5.9) 229 (5.9) 221 (6.1) 1089 (5.8)
Candida species 64 (9.2) 65 (4.9) 108 (5.2) 165 (5.3) 222 (5.6) 271 (7.0) 185 (5.1) 1080 (5.8)
Acinetobacter species 41 (5.9) 78 (5.9) 102 (5.0) 163 (5.2) 225 (5.7) 233 (6.0) 206 (5.7) 1048 (5.6)
Pseudomonas species 27 (3.9) 85 (6.4) 98 (4.8) 109 (3.5) 170 (4.3) 182 (4.7) 157 (4.2) 828 (4.4)
Enterococcus species 16 (2.3) 33 (2.5) 51 (2.5) 80 (2.6) 119 (3.0) 133 (3.4) 109 (3.0) 541 (2.9)
Enterobacter species 16 (2.3) 31 (2.3) 38 (1.8) 81 (2.6) 114 (2.9) 100 (2.6) 93 (2.5) 473 (2.5)
Other 84 (12.1) 148 (11.1) 233 (11.3) 448 (14.2) 454 (11.5) 497 (12.7) 435 (12.0) 2299 (12.3)
Number of isolates 695 1334 2062 3134 3943 3887 3640 18 695
CoNS, coagulase-negative staphylococci.
a Typhi and Paratyphi.
Figure 3. Resistance trends of Salmonella Typhi in India, 2008–2014 (error bars indicate the 95% conﬁdence interval).
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frequently isolated in blood cultures. Salmonella species associated
with enteric fever were the most frequently isolated Gram-
negative organisms, followed by E. coli and Klebsiella species.
Although CoNS represented the organisms most frequently
isolated, this is likely because CoNS are a common contaminant
in clinical specimens.11 This study provides evidence that enteric
fever is the major cause of bacteremia primarily affecting children
and young adults, justifying the need for improvements in
sanitation and indicating the urgent need for a vaccine conferring
long-term immunity. The low percentage of polymicrobial cultures
(66 of 18 695 positive blood cultures) may indicate a low
percentage of surgical patients in this database.
High resistance rates to both frontline antibiotics and those of
last-resort were observed for all Gram-negative organisms isolated
from blood cultures, but resistance was not static over the period of
the study. For Salmonella Typhi and Salmonella Paratyphi A,
nalidixic acid resistance rates remained extremely high (>95%),
consistent with other studies performed in India,3,12 while
resistance rates to older antibiotics, ampicillin and trimetho-
prim–sulfamethoxazole, decreased over time. Similar ﬁndings
were observed in single-center studies in India, with increasing
susceptibility to older antibiotics like ampicillin, chloramphenicol,
and trimethoprim–sulfamethoxazole.13,14 These changes are likely
due to the replacement of these drugs as an empiric treatmentoption for enteric fever with newer drugs, such as the ﬂuoroqui-
nolones. These ﬁndings suggest that ﬂuoroquinolones can no
longer be considered an empiric treatment option for suspected
enteric fever; rather, physicians may be able to use older drugs
again or third-generation cephalosporins (resistance to cephalos-
porins was minimal). Unfortunately, third-generation cephalospo-
rin-resistant Salmonella Typhi and Salmonella Paratyphi A strains
have emerged; these constituted about 0.8% of the isolates in this
study, consistent with other studies in India.3,12
The resistance rates of E. coli to ﬂuoroquinolones and third-
generation cephalosporins remained high throughout the study
period; both were above 80% in 2014. High resistance rates were
also observed for other antibiotics frequently used as empiric
treatment options for E. coli, such as aminoglycosides (61.1%) and
piperacillin–tazobactam (37.7%). Most alarming was the high
carbapenem resistance, which was greater than 10%, a rate that is
signiﬁcantly higher than in other countries from which surveil-
lance data are available. Of 41 countries with data from 2013 or
2014, only 12 reported detecting carbapenem resistance in E. coli
and only three recorded a rate greater than 3%: Bulgaria (3.5%),
Turkey (5%), and Vietnam (9%).15 Carbapenem resistance rates for
K. pneumoniae also increased signiﬁcantly over the study period,
reaching approximately 60% by the end of the study, which again is
higher than any other country except Greece, which had a similar
percentage of carbapenem resistance in 2013 (60%).16 The rising
Table 3
Percentage of pathogenic isolates resistant (including intermediate isolates) to selected antibiotics, 2008–2014
Organism,
antibiotics
2008 2009 2010 2011 2012 2013 2014 p-Valueb
Resistance,
% (95% CIa)
Resistance,
% (95% CIa)
Resistance,
% (95% CIa)
Resistance,
% (95% CIa)
Resistance,
% (95% CIa)
Resistance,
% (95% CIa)
Resistance,
% (95% CIa)
Escherichia coli
Fluoroquinolonesc 82.5 (71.4–90.0) 90.3 (84.8–93.9) 87.8 (82.4–91.6) 88.8 (84.8–91.8) 85.2 (81.8–88.1) 84.8 (81.2–87.7) 85.1 (81.4–88.1) 0.114
3rd-generation
cephalosporinsd
-g -g 76.9 (70.5–82.3) 79.2 (74.0–83.5) 81.6 (77.8–84.8) 80.3 (76.4–83.8) 83.3 (79.4–86.5) 0.588
Carbapenemse -g -g -g 7.8 (5.2–11.5) 12.6 (9.7–16.2) 10.5 (8.0–13.7) 11.5 (8.8–14.9) 0.332
Aminoglycosidesf 61.3 (48.9–72.4) 74.6 (67.4–80.6) 70.4 (63.7–76.4) 66.8 (61.4–71.8) 70.1 (65.9–74.0) 63.2 (58.7–67.5) 61.1 (56.5–65.6) 0.003
Piperacillin–tazobactam 36.1 (25.2–48.7) 29.9 (23.4–37.3) 28.1 (22.2–34.7) 30.2 (25.3–35.6) 41.5 (37.2–46.0) 34.1 (29.8–38.6) 37.7 (33.2–42.3) 0.021
Colistin - - - 0.0 (0.0–27.8) 3.4 (1.3–8.4) 1.1 (0.3–3.8) 3.1 (1.4–6.6) 0.785
Klebsiella pneumoniae
Fluoroquinolonesc 85.7 (73.3–92.9) 75.6 (65.1–83.8) 76.2 (68.1–82.7) 84.4 (78.8–88.7) 76.7 (71.4–81.2) 80.3 (75.4–84.4) 72.9 (67.8–77.4) 0.081
3rd-generation
cephalosporinsd
-g -g 83.9 (76.6–89.2) 89.6 (84.6–93.1) 86.2 (81.7–89.8) 85.5 (81.0–89.0) 79.9 (75.2–83.9) 0.029
Carbapenemse -g -g -g 41.5 (34.6–48.8) 52.4 (46.2–58.6) 60.4 (54.6–65.8) 56.6 (51.1–61.9) <0.001
Aminoglycosidesf 88.0 (76.2–94.4) 71.8 (61.0–80.6) 76.2 (68.1–82.7) 81.8 (75.9–86.5) 79.1 (74.0–83.4) 79.6 (74.7–83.8) 71.1 (66.0–75.8) 0.062
Piperacillin–tazobactam 54.5 (40.0–68.3) 50.6 (39.7–61.5) 58.9 (50.3–67.0) 67.7 (60.9–73.7) 65.9 (60.2–71.3) 68.1 (62.6–73.2) 62.7 (57.3–67.7) 0.052
Colistin - - - 0.0 (0.0–48.9) 4 (1.6–9.9) 1.1 (0.3–3.8) 3.2 (1.4–7.3) 0.936
Salmonella Typhi
Ampicillin 13.1 (8.0–20.8) 11.4 (7.1–17.6) 8.01 (5.4–11.7) 8.1 (6.0–10.8) 5.0 (2.9–8.3) 9.0 (6.5–12.3) 5.3 (3.2–8.6) 0.018
Fluoroquinolonesc 100 (20.7–100) 100 (75.8–100) 100 (92.6–100) 97.6 (87.4–99.6) 96.2 (81.1–99.3) 95.5 (78.2–99.2) 97.5 (87.1–99.6) 0.269
Trimethoprim–
sulfamethoxazole
17.1 (10.1–27.6) 15.8 (10.6–22.9) 9.2 (6.4–13.2) 8.4 (6.2–11.3) 4.2 (2.5–7.1) 9.0 (6.4–12.4) 4.2 (1.6–10.2) <0.001
3rd-generation
cephalosporinsd
-g -g 1.7 (1.0–4.0) 0.8 (0.3–2.0) 2.2 (1.1–4.3) 1.0 (0.4–2.7) 1.7 (0.7–3.9) 0.815
S/I/Rh 282/3/2 512/3/1 350/6/2 377/0/4 294/0/5
Salmonella Paratyphi A
Ampicillin 4.2 (0.1–20.2) 4.5 (1.5–12.4) 2.1 (0.6–7.2) 3.1 (1.4–6.5) 2.5 (0.9–7.2) 1.5 (0.4–5.3) 2.7 (0.7–9.3) 0.366
Fluoroquinolonesc - 100 (72.2–100) 100 (80.6–100) 100 (78.5–100) 100 (51–100) 88.9 (56.5–98) 85.7 (60.1–96) 0.023
Trimethoprim–
sulfamethoxazole
0.0 (0.0–22.8) 1.6 (0.3–8.7) 3.1 (1.1–8.7) 1.1 (0.3–3.9) 1.4 (0.4–5.1) 0.0 (0.0–3.2) 0.0 (0.0–12.8) 0.168
3rd-generation
cephalosporinsd
-g -g 1.0 (0.2–5.6) 3.5 (1.7–7.0) 2.1 (0.7–6.0) 2.2 (1.0–6.3) 3.8 (1.3–10.6) 0.600
S/I/Rh - - 96/1/0 195/6/1 140/2/1 132/1/2 76/0/3
Pseudomonas aeruginosa
Ceftazidime, cefepime 85.0 (63.9–94.8) 78.3 (67.2–86.4) 89.3 (80.9–94.3) 78.3 (68.3–85.8) 73.2 (64.7–80.2) 67.1 (59.3–74.1) 67.9 (57.3–76.9) <0.001
Carbapenemse -g -g -g -g 49.1 (40.2–58.1) 50.3 (42.4–58.3) 46.8 (36.2–57.7) 0.792
Aminoglycosidesf 75.0 (53.1–88.8) 58.0 (46.2–68.9) 71.8 (61.4–80.2) 65.1 (54.6–74.3) 53.7 (44.9–62.2) 57.2 (49.3–64.8) 56.6 (45.9–66.8) 0.044
Piperacillin–tazobactam -g -g -g -g 41.3 (33.0–50.2) 56.8 (48.7–64.6) 61.8 (50.6–71.9) <0.001
Colistin - - - 0.0 (0.0–65.8) 3.8 (1.0–12.8) 2.2 (0.6–7.7) 0.0 (0.0–7.6) 0.194
Acinetobacter species
Carbapenemse 73.2 (58.1–84.3) 72.6 (61.4–81.5) 65.4 (55.7–73.9) 73.4 (65.9–79.8) 71.1 (64.6–76.8) 67.3 (60.7–73.3) 67.3 (59.6–74.2) 0.362
Colistin - - - - 2.5 (0.9–7.2) 5.9 (2.9–11.7) 4.1 (1.4–11.3) 0.435
CoNS
Oxacillin 82.0 (69.2–90.2) 75.8 (69.8–80.8) 70.7 (66.8–74.4) 78.2 (73.5–82.3) 77.0 (73.2–80.3) 72.9 (68.7–76.8) 61.6 (56.3–66.7) 0.003
Vancomycin 0.0 (0.0–3.3) 0.0 (0–1.3) 0.0 (0.0–0.7) 0.0 (0.0–0.6) 0.0 (0.0–0.4) 0.0 (0.0–0.5) 0.6 (0.2–1.7) 0.011
S/I/Rh 113/1/0 300/0/0 576/1/0 614/2/0 964/2/0 708/2/0 513/1/3
Linezolid 0.0 (0.0–3.9) 0.0 (0.0–1.5) 0.0 (0.0–0.7) 0.0 (0.0–0.7) 0.0 (0.0–0.4) 0.1 (0.0–0.8) 2.5 (1.5–4.1) <0.001
Staphylococcus aureus
Oxacillin 50.0 (30.7–69.3) 28.6 (18.9–40.7) 48.7 (37.8–59.7) 40.7 (30.9–51.3) 53.1 (44.5–61.4) 40.0 (32.0–48.6) 46.5 (37.1–56.2) 0.342
Vancomycin 0.0 (0.0–6.2) 0.0 (0.0–5.7) 1.4 (0.2–7.4) 0.6 (0.1–3.6) 2.4 (1.1–5.6) 0.0 (0.0–2.0) 2.2 (0.9–5.6) 0.218
S/I/Rh 58/0/0 63/0/0 72/0/1 152/1/0 199/5/0 184/0/0 176/4/0
Linezolid 13.3 (6.3–26.2) 0.0 (0.0–6.3) 0.0 (0.0–5.1) 0.0 (0.0–2.6) 2.6 (1.1–6.0) 0.5 (0.0–3.0) 3.3 (1.5–7.0) 0.198
S.
 G
a
n
d
ra
 et
 a
l.
 /
 In
tern
a
tio
n
a
l
 Jo
u
rn
a
l
 o
f
 In
fectio
u
s
 D
isea
ses
 5
0
 (2
0
1
6
)
 7
5
–
8
2
 
7
9
T
a
b
le
3
(C
o
n
ti
n
u
ed
)
O
rg
a
n
is
m
,
a
n
ti
b
io
ti
cs
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
p
-V
a
lu
e
b
R
e
si
st
a
n
ce
,
%
(9
5
%
C
Ia
)
R
e
si
st
a
n
ce
,
%
(9
5
%
C
Ia
)
R
e
si
st
a
n
ce
,
%
(9
5
%
C
Ia
)
R
e
si
st
a
n
ce
,
%
(9
5
%
C
Ia
)
R
e
si
st
a
n
ce
,
%
(9
5
%
C
Ia
)
R
e
si
st
a
n
ce
,
%
(9
5
%
C
Ia
)
R
e
si
st
a
n
ce
,
%
(9
5
%
C
Ia
)
E
n
te
ro
co
cc
u
s
fa
ec
iu
m
A
m
p
ic
il
li
n
7
5
.0
(3
0
.1
–
9
5
.4
)
1
0
0
(7
0
.1
–
1
0
0
)
8
3
.9
(6
7
.4
–
9
2
.9
)
8
0
.9
(6
7
.5
–
9
2
.9
)
9
2
.7
(8
2
.7
–
9
7
.1
)
9
2
.2
(8
3
.0
–
9
6
.6
)
9
7
.1
(8
5
.5
–
9
9
.5
)
0
.0
4
0
V
a
n
co
m
y
ci
n
0
.0
(0
.0
–
4
3
.4
)
0
.0
(0
.0
–
2
7
.8
)
3
2
.3
(1
8
.6
–
4
9
.9
)
1
7
.8
(9
.3
–
3
1
.3
)
1
8
.5
(1
0
.4
–
3
0
.8
)
1
6
.4
(9
.4
–
2
7
.1
)
1
0
.5
(4
.2
–
2
4
.1
)
0
.4
5
9
E
n
te
ro
co
cc
u
s
fa
ec
a
li
s
A
m
p
ic
il
li
n
-
1
4
.3
(2
.6
–
5
1
.3
)
1
3
.3
(3
.7
–
3
7
.9
)
3
.7
(0
.7
–
1
8
.3
)
1
3
.2
(5
.8
–
2
7
.3
)
1
1
.6
(5
.1
–
2
4
.5
)
1
6
.2
(7
.7
–
3
1
.1
)
0
.4
8
7
V
a
n
co
m
y
ci
n
-
0
.0
(0
.0
–
3
2
.4
)
5
.9
(1
.0
–
2
7
.0
)
4
.0
(0
.7
–
1
9
.5
)
0
.0
(0
.0
–
9
.4
)
0
.0
(0
.0
–
7
.7
)
5
.6
(1
.5
–
1
8
.1
)
0
.0
9
5
C
o
N
S
,
co
a
g
u
la
se
-n
e
g
a
ti
v
e
st
a
p
h
y
lo
co
cc
i.
a
W
il
so
n
9
5
%
co
n
ﬁ
d
e
n
ce
in
te
rv
a
l.
b
p
-V
a
lu
e
s
o
b
ta
in
e
d
u
si
n
g
th
e
C
o
ch
ra
n
–
A
rm
it
a
g
e
te
st
.
c
Fl
u
o
ro
q
u
in
o
lo
n
e
s
in
cl
u
d
e
ci
p
ro
ﬂ
o
x
a
ci
n
a
n
d
le
v
o
ﬂ
o
x
a
ci
n
(n
a
li
d
ix
ic
a
ci
d
fo
r
S
a
lm
o
n
e
ll
a
T
y
p
h
i
a
n
d
P
a
ra
ty
p
h
i
A
).
d
T
h
ir
d
-g
e
n
e
ra
ti
o
n
ce
p
h
a
lo
sp
o
ri
n
s
in
cl
u
d
e
ce
ft
ri
a
x
o
n
e
,
ce
fo
ta
x
im
e
,
a
n
d
ce
ft
a
zi
d
im
e
.
e
C
a
rb
a
p
e
n
e
m
s
in
cl
u
d
e
im
ip
e
n
e
m
a
n
d
m
e
ro
p
e
n
e
m
.
f
A
m
in
o
g
ly
co
si
d
e
s
in
cl
u
d
e
g
e
n
ta
m
ic
in
,
to
b
ra
m
y
ci
n
,
a
n
d
a
m
ik
a
ci
n
.
g
R
e
si
st
a
n
ce
p
e
rc
e
n
ta
g
e
s
n
o
t
d
is
p
la
y
e
d
,
a
s
m
in
im
u
m
in
h
ib
it
o
ry
co
n
ce
n
tr
a
ti
o
n
(M
IC
)
v
a
lu
e
s
ch
a
n
g
e
d
d
u
ri
n
g
th
e
st
u
d
y
p
e
ri
o
d
.
h
S
,
su
sc
e
p
ti
b
le
;
I,
in
te
rm
e
d
ia
te
;
R
,
re
si
st
a
n
t.
S. Gandra et al. / International Journal of Infectious Diseases 50 (2016) 75–8280carbapenem resistance among E. coli and K. pneumoniae isolates is
a cause for concern, given the frequency of infections caused by
these and the associated mortality, which for carbapenem-
resistant K. pneumoniae bacteremia is estimated to be about
50%.17 The primary drug for treating carbapenem-resistant strains
of K. pneumoniae and E. coli is colistin; however, worryingly,
colistin resistance has already emerged. Colistin-resistant strains
of P. aeruginosa and Acinetobacter species have also emerged. This is
signiﬁcant because these pathogens are intrinsically resistant to
several antibiotics, leaving physicians with few options to treat
infections.
Among Gram-positive organisms, S. aureus and Enterococcus
species were the most frequently isolated organisms after CoNS.
Methicillin resistance in CoNS was very high at 73%, consistent
with other studies in India;18–20 however CoNS remain highly
susceptible to vancomycin and linezolid. Similar to a multicen-
ter study in India,2 the proportion of S. aureus isolates that
were resistant to methicillin was high in this study (42% in the
multicenter study vs. 44% in this study); however, of more
signiﬁcance were the isolates that were resistant to vancomycin
and linezolid. Although S. aureus remains highly susceptible to
both drugs, 3% of the isolates were linezolid-resistant in
2014. Several other studies in India have reported similar
frequencies of LRSA, consistent with this ﬁnding.21–23 In the
present study, two cases of VRSA were observed; however,
vancomycin resistance in Enterococcus species was much
higher, with 17% of the E. faecium isolates being vancomycin-
resistant. Efforts have been made in the USA to reduce the threat
posed by VRSA through reporting standards for infections
caused by these pathogens.24 Similar efforts may be necessary
in India, because genes conferring resistance, once they have
evolved, can spread rapidly both within a country and around
the world.
In this study, the resistance rates were also examined by
age and sex. No signiﬁcant differences were found (data not
shown).
As with most large data surveillance studies, this study has
limitations. First, although the analysis was conﬁned to blood
isolates, which likely portend infection, no clinical information was
included. Second, information on variables differentiating com-
munity-acquired from healthcare-acquired infections was not
available. However, enteric fever caused by Salmonella species
(Salmonella Typhi and Paratyphi A) is a common cause of
community-acquired bloodstream infection.25 Thus, it is likely
that most if not all Salmonella cultures identiﬁed had a community
origin. Third, although the data are national in scale, they may not
be nationally representative of all Indian states or types of
healthcare facility. Finally, MIC values were not available to re-
interpret the resistance percentage for years prior to the change in
MIC breakpoints. However, for the majority of pathogen and
antibiotic combinations (28 of 37 combinations), the MIC values
did not change during the study period.
In conclusion, increased antibiotic use has long been directly
linked to higher rates of antibiotic resistance.26,27 With the highest
volume of antibiotic sales in 2010,28 it is not surprising that India
has a simmering public health crisis related to antibiotic
resistance. The increasing consumption of the two antibiotics of
last-resort, carbapenems and polymyxins, between 2000 and 2010,
portends a likely rise in the proportion of Gram-negative
organisms resistant to these two antibiotic classes. As has been
demonstrated before, resistance in India can spread rapidly to
other parts of the world,29 making these results important not just
for India. These results also indicate the urgent need for new
antibiotics against Gram-negative organisms, as well as the
necessity of continued surveillance of resistance patterns, espe-
cially in the Gram-negative organisms. Finally, the implementation
Figure 4. Carbapenem resistance trends among multiple organisms in India, 2008–2014 (error bars indicate the 95% conﬁdence interval). For E. coli and K. pneumoniae, data
are presented only from 2011, as the minimum inhibitory concentration (MIC) values were lowered in June 2010. For P. aeruginosa, data are presented from 2012, as MIC
values were lowered in January 2012. For Acinetobacter species, MIC values were lowered in January 2014, and thus there is a possibility that resistance for the years 2008–
2013 is underestimated.
S. Gandra et al. / International Journal of Infectious Diseases 50 (2016) 75–82 81of standard infection control practices and antimicrobial steward-
ship programs in healthcare facilities should be a priority.
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